Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Combinations in R/R Multiple Myeloma
NCT03314181Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2018
- Primary completion
- May 2031
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of venetoclax in multiple myeloma (MM), sponsored by AbbVie Inc.. Started Apr 2018; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03314181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03314181.